A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy

• Chloé B. Steen,
• Ellen Leich,
• June H. Myklebust,
• Sandra Lockmer,
• Jillian F. Wise,
• Björn E. Wahlin,
• Bjørn Østenstad,
• Knut Liestøl,
• Eva Kimby,
• Andreas Rosenwald,
• Erlend B. Smeland,
• Harald Holte,
• Ole Christian Lingjærde,
• Marianne Brodtkorb

Affiliations

Chloé B. Steen

Department of Informatics, University of Oslo, Oslo, Norway;Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

Ellen Leich

Institute of Pathology, University of Würzburg and Comprehensive Cancer Centre Mainfranken, Germany

June H. Myklebust

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

Sandra Lockmer

Division of Haematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden

Jillian F. Wise

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

Björn E. Wahlin

Division of Haematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden

Bjørn Østenstad

Department of Oncology, Oslo University Hospital, Oslo, Norway

Knut Liestøl

Department of Informatics, University of Oslo, Oslo, Norway;Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

Eva Kimby

Division of Haematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden

Andreas Rosenwald

Institute of Pathology, University of Würzburg and Comprehensive Cancer Centre Mainfranken, Germany

Erlend B. Smeland

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

Harald Holte

KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;Department of Oncology, Oslo University Hospital, Oslo, Norway

Ole Christian Lingjærde

Department of Informatics, University of Oslo, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

Marianne Brodtkorb

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;Department of Oncology, Oslo University Hospital, Oslo, Norway